Can Volume Keep Covering Eli Lilly’s Price Cuts

Eli Lilly (LLY) grew revenue 48% in Q2 2026, driven by Zepbound and Mounjaro. A more understated metric for investors to watch is pricing. Lilly's U.S. price fell 9% from a year earlier, excluding changes to rebate estimates. So far, volume covers that cut. The risk is the quarter it cannot.

Lilly's Price Cuts Run Deeper Than The Reported Figure

As reported, Lilly's U.S. price declined 3% in Q2 2026, led by Zepbound and Mounjaro. That figure benefited from changes to estimates for rebates and discounts. Excluding them, the decline was 9%, the figure this risk rests on.

Q1 2026 looked much the same, with U.S. price down 10% excluding a rebate adjustment. Consequently, the reported metric masks underlying price concessions. The CFO does not expect these rebate adjustments to continue into the second half of 2026.

And Lilly Expects That Price To Keep Falling

When Zepbound lost access at CVS in July 2025, patients could switch to a competitor, pay cash or seek a medical exception, the CFO said. The CEO has said a reasonable amount of use through medical exceptions and for sleep apnea moves at close to an undiscounted price. Lilly's management announced it has reached an agreement to restore preferred access at CVS Caremark beginning in Q4 2026, and the CFO called the medical exception route "maybe a short-term thing."

Management expects price to go down as access opens up to all patients, and says the drop is already built into its raised full-year guidance. Lilly expects to more than offset the lower price with volume growth.

So Far, Lilly Sells Enough Extra To Cover It

U.S. revenue grew 33% in Q2 2026, mainly on volume growth from Zepbound and Mounjaro. In the U.S. incretin obesity market, total prescriptions grew 78% in Q2 2026, and about 6 in 10 were for a Lilly medicine. The CEO has said nearly every price cut brings a large expansion in volume, while conceding there is a floor.

But the gap between volume and price narrowed from Q1 2026 to Q2 2026. U.S. revenue growth, as reported, slowed from 43% to 33%, while the price decline excluding rebate adjustments only eased from 10% to 9%. And the growth is concentrated: of the almost $6.8 billion added versus Q2 2025 by the group Lilly calls its Key Products, Mounjaro and Zepbound supplied $6.3 billion.

You Are Betting Volume Keeps Outrunning Price

Operating profitability sits near a peak. Lilly's trailing twelve-month operating margin reached 49.7%, compared to its three-year average of 39.0%.

At 38 times trailing earnings, the share price likely assumes volume keeps winning. The shares sit about 11% below their 52-week high, and options traders are not bracing for much: implied volatility is in the 35th percentile of its one-year range. Compare that across stocks on our option implied volatility screen.

This is a risk to weigh rather than a break in the story. What would change the read is if the U.S. price decline, excluding rebate adjustments, widens beyond 10% once CVS access begins in Q4 2026.

Could One Warning Sign Cost You Years Of Gains?

A warning in the fundamentals is manageable when you are diversified and dangerous when you are not. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.